C
카나프테라퓨틱스
0082N0KOSDAQ자연과학 및 공학 연구개발업45.5 / 100
Reference Date: 2026-06-10
Financial Score20.0 / 40
News Sentiment12.5 / 25
Momentum3.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is low with sound financial health. Plunged 41.8% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Canapharmaceuticals is an innovative biopharmaceutical company developing novel drugs for oncology and ophthalmic diseases using human genome-based technology. The company has a diverse pipeline of seven projects, including bispecific antibodies, ADCs, and synthetic drugs, and has secured significant revenue through early-stage technology transfers and co-development partnerships with major pharmaceutical firms in South Korea.
Number of Employees
23people
Average Salary
55.1M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 62.704.0Point
PBR
—Industry Average 3.243.5Point
ROE
—Industry Average -32.093.5Point
Debt Ratio
5.73Industry Average 7.314.0Point
In line with industry avg
Trend 5.0 / 10 points
Revenue Growth Rate
1.5 / 3
Operating Profit Growth Rate
1.5 / 3
ROE Trend
2.0 / 4
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (0%, downtrend)
Current 19,050Won52-week high 52,20052-week low 19,050
1-month return0.0Point
1m -41.83% (strong drop)
Volume trend2.0Point
Volume decreasing
Detailed Disclosure
5 totalPositive 0Neutral 5Negative 0
- Neutral주식매수선택권부여에관한신고2026-05-28
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-22
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-22
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-22
- Neutral분기보고서 (2026.03)2026-05-13